A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Ascending Intravenous Doses of FB825
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2016
At a glance
- Drugs FB 825 (Primary)
- Indications Allergic asthma; Allergic rhinitis; Atopic dermatitis
- Focus Adverse reactions
- Sponsors Fountain BioPharma
- 03 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 27 Nov 2015 Planned number of patients changed from 42 to 54 as reported by ClinicalTrials.gov.
- 27 Nov 2015 Planned End Date changed from 1 Mar 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov.